Development History of Ipamorelin: From Selective GHS Discovery to Current Research Applications
DISCLAIMER: This article is for educational and scientific research reference purposes only. Ipamorelin is not approved by the FDA for use in humans or animals. Palmetto Peptides sells Ipamorelin exclusively for in vitro and preclinical laboratory research. Nothing in this article constitutes medical advice.
Development History of Ipamorelin: From Selective GHS Discovery to Current Research Applications
Last Updated: March 27, 2026 | Reading Time: Approximately 10 minutes | Author: Palmetto Peptides Research Team
Quick Answer
Ipamorelin was first described in peer-reviewed literature in 1998 by researchers at Novo Nordisk A/S in Denmark, who characterized it as the first growth hormone secretagogue to demonstrate selective GH release with minimal cortisol and ACTH stimulation in animal models. Its development came out of a decades-long research program dating back to the 1970s that progressively refined the structure-activity relationships of GH secretagogue peptides. Today, Ipamorelin remains an active research tool compound used in preclinical GH axis research worldwide.
Era 1: The Foundations (1970s to Late 1980s)
Bowers and the Discovery of Peptide GH Secretagogues
The story of Ipamorelin begins more than two decades before the compound itself was synthesized. In the 1970s, Cyril Bowers and colleagues at Tulane University were studying a class of naturally occurring peptides called enkephalins, which are small peptides involved in pain modulation that act on opioid receptors in the brain.
While exploring the effects of enkephalin analogs on pituitary function, Bowers made a key observation: certain structural modifications to enkephalin-related peptides produced compounds that stimulated GH release. This effect appeared to be independent of the classical opioid receptor system and instead involved a separate, previously uncharacterized receptor pathway.
This discovery was significant because it revealed that synthetic peptides could stimulate pituitary GH release through a mechanism distinct from the already-known GHRH pathway. Bowers coined the term growth hormone secretagogues (GHS) for this class of compounds.
GHRP-6: The First-Generation Research Tool
From Bowers' initial observations, subsequent structure-activity relationship (SAR) work led to the development of GHRP-6 (Growth Hormone Releasing Peptide 6), a hexapeptide (six amino acid chain) that became the primary research tool for studying GH secretagogue biology through the late 1980s and 1990s.
GHRP-6 (sequence: His-DTrp-Ala-Trp-DPhe-Lys-NH2) demonstrated robust GH-stimulating activity in multiple animal models and became widely used in preclinical research. However, researchers noted that GHRP-6 also stimulated the release of cortisol, ACTH, and prolactin at GH-effective doses, which introduced confounding variables in research experiments.
This limitation of GHRP-6 set the stage for the next phase of GHS research: the pursuit of more selective compounds.
Era 2: Receptor Identification and the Selectivity Problem (Late 1980s to Mid-1990s)
The Receptor Mystery
For over a decade after Bowers' initial discovery, the receptor that GHS peptides were acting on remained unidentified. Researchers knew that GHRP-6 and related compounds were producing their effects through a receptor distinct from the GHRH receptor and the opioid receptors, but the molecular identity of this receptor was unknown.
This gap in understanding made it difficult to rationally design more selective compounds because the structural features of the target were not yet characterized. Research during this period was largely empirical: synthesize a new structural variant, test it in an animal model, measure GH and other hormone responses, and use the data to guide the next round of synthesis.
GHRP-2: Higher Potency, Similar Selectivity Issues
During this period, researchers developed GHRP-2, a structural variant with substantially higher GH-stimulating potency than GHRP-6 in preclinical models. However, GHRP-2 carried similar or greater selectivity concerns regarding cortisol and prolactin stimulation. Higher potency had been achieved, but the selectivity problem remained.
The Howard et al. (1996) Receptor Discovery
A transformative moment came in 1996 with the publication of a landmark paper by Howard et al. in the journal Science. The team successfully cloned and characterized a receptor in the pituitary and hypothalamus that mediated the effects of GHS peptides. This receptor was initially called the GHS receptor, later renamed GHSR-1a when additional receptor variants were identified.
In plain terms: researchers had finally identified the lock that GHS peptides were acting on. This discovery opened the door to structure-based research approaches, where new compounds could be designed with knowledge of the receptor's structural requirements.
The Howard et al. discovery earned the GHSR-1a the status of one of the most important receptor discoveries in neuroendocrinology of that era, and it set the stage for the next major development: the discovery of ghrelin.
Era 3: Ipamorelin's Development and Characterization (1997 to 1998)
The Novo Nordisk Research Program
Against this backdrop, researchers at Novo Nordisk A/S, the Danish pharmaceutical company, were pursuing a systematic program to develop improved GHS compounds with better selectivity profiles. The research team, including Karsten Raun, Birgitte Sehansen, Niels Johansen, Michael Ankersen, and colleagues, applied the growing understanding of GHSR-1a receptor pharmacology to design new peptide structures.
The challenge they set for themselves was specific: could they design a ghrelin receptor agonist that produced robust GH release (comparable to GHRP-6 and GHRP-2) while achieving greater selectivity, particularly regarding cortisol and ACTH stimulation?
The Structural Design Rationale
The Novo Nordisk team applied systematic structure-activity relationship (SAR) analysis to existing GHS peptide scaffolds. They tested numerous structural variants, modifying amino acid composition, stereochemistry (L vs. D forms), side chain structure, and terminal modifications.
The key structural insights that emerged from this work, several of which were published in a 1998 paper in the Journal of Medicinal Chemistry by Ankersen and colleagues, included:
- Incorporating Aib (alpha-aminoisobutyric acid) at the N-terminus provided conformational constraints that appeared to favor GH selectivity
- Using D-2-Naphthylalanine (a larger aromatic D-amino acid) at position 3 enhanced receptor affinity while contributing to selectivity
- The amide C-terminus improved stability against carboxypeptidase degradation
- Limiting the chain to five residues (pentapeptide) rather than the six of GHRP-6 and GHRP-2 contributed to the selectivity profile
The compound that emerged from this work, with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, was named Ipamorelin.
The 1998 Characterization Papers
The definitive characterization of Ipamorelin was published in two papers in 1998:
Raun et al. (1998), European Journal of Endocrinology: This paper characterized Ipamorelin's GH-releasing activity and selectivity profile in rat and swine models, comparing it directly to GHRP-6. The authors concluded that Ipamorelin was "the first GHRP receptor agonist with a selectivity for GH release similar to that displayed by GHRH," a landmark characterization in the GHS field.
Ankersen et al. (1998), Journal of Medicinal Chemistry: This companion paper described the broader medicinal chemistry program that produced Ipamorelin, detailing the structure-activity relationships and the rationale for the key structural features.
Together, these two papers established Ipamorelin as the most selective GHSR-1a agonist characterized to date and introduced it to the broader research community as a valuable tool compound.
Era 4: Ghrelin Discovery and the Broader Context (1999 Onward)
Ghrelin: Ipamorelin's Natural Counterpart
In 1999, just one year after Ipamorelin's characterization, the natural ligand for GHSR-1a was finally identified. Kojima et al. published the discovery of ghrelin in the journal Nature, characterizing it as a 28-amino acid acylated peptide produced primarily in the stomach that activates GHSR-1a and stimulates GH release.
This discovery retroactively explained the biological system that Ipamorelin had been designed to interact with. It also reframed GHSR-1a from a "growth hormone secretagogue receptor" to the "ghrelin receptor," and it revealed that the receptor was involved in a much broader biological system than just GH regulation, including appetite regulation, metabolic signaling, and energy homeostasis.
The discovery of ghrelin added scientific depth to the research interest in GHSR-1a agonists like Ipamorelin, opening new research questions about how selective versus broad ghrelin receptor agonism might differentially affect these multiple physiological functions.
Bone and Metabolic Research (2000 Onward)
Following the initial GH selectivity characterization, research with Ipamorelin expanded into new biological domains. The Svensson et al. (2000) bone study in the Journal of Endocrinology demonstrated effects on bone mineral content in adult female rats, opening a line of investigation into GH-mediated skeletal biology.
Researchers also began exploring Ipamorelin in the context of metabolic research, using it as a tool to study how GH stimulation influences body composition parameters in animal models. These studies built on the growing understanding of the GH/IGF-1 axis as a regulator of fat distribution and lean tissue maintenance in preclinical systems.
Era 5: Current Research Applications
Ipamorelin as a Reference Compound
Today, Ipamorelin occupies a well-established position in the GH secretagogue research literature as a selective reference standard. New GHSR-1a agonists developed by pharmaceutical and academic researchers are often compared against Ipamorelin's selectivity profile as a benchmark.
Its characterization is well-established enough that it appears in reviews and research methodology sections as a known quantity, giving researchers a stable reference point for interpreting their own experimental data.
Ongoing Research Areas
Current preclinical research using Ipamorelin includes:
- Receptor pharmacology studies exploring the molecular basis of GHSR-1a selectivity and biased agonism
- GH pulsatility research investigating how ghrelin receptor activation shapes GH release patterns in animal models
- Combination studies pairing Ipamorelin with CJC-1295 or other GH axis compounds to study dual-pathway stimulation
- Metabolic and body composition research examining how GH secretagogues influence fat and lean tissue partitioning in rodent models
For details on any of these current applications, see the related articles listed below.
Timeline Summary
| Year | Development |
|---|---|
| 1970s | Cyril Bowers discovers peptide GH secretagogues; GHRP research begins |
| Late 1980s | GHRP-6 established as primary GHS research tool |
| Early 1990s | GHRP-2 developed with higher potency; selectivity concerns remain for both |
| 1996 | Howard et al. clone and characterize GHSR-1a (the ghrelin receptor) |
| 1997-1998 | Novo Nordisk team develops Ipamorelin through systematic SAR work |
| 1998 | Raun et al. publish foundational Ipamorelin characterization papers |
| 1999 | Ghrelin discovered by Kojima et al.; natural GHSR-1a ligand identified |
| 2000 | Svensson et al. publish Ipamorelin bone mineral content findings in rats |
| 2000s-present | Ipamorelin used as selective reference tool in GH axis research globally |
Table 1: Development timeline of Ipamorelin from GHS research origins to current applications.
Research-grade Ipamorelin is available from Palmetto Peptides for qualified researchers building on this established body of preclinical science.
Related Research
- Complete Guide to Ipamorelin
- Ipamorelin Mechanism of Action
- Key Animal Studies on Ipamorelin
- Chemical Structure and Synthesis of Ipamorelin
- Ipamorelin vs GHRP-2 and GHRP-6
- Pharmacokinetics of Ipamorelin
Frequently Asked Questions
When was Ipamorelin first characterized in peer-reviewed research?
Ipamorelin was first characterized in 1998 by Raun and colleagues at Novo Nordisk A/S, published in the European Journal of Endocrinology. It was described as the first selective growth hormone secretagogue.
Who developed Ipamorelin?
Ipamorelin was developed by researchers at Novo Nordisk A/S in Denmark, led by Karsten Raun and colleagues including Birgitte Sehansen, Niels Johansen, and Michael Ankersen.
What historical research led to Ipamorelin's development?
Ipamorelin emerged from decades of GHS research beginning with Cyril Bowers' discovery in the 1970s that certain peptides could stimulate GH release. The development of GHRP-6 and GHRP-2, the identification of the GHSR-1a receptor in 1996, and systematic SAR work at Novo Nordisk all contributed to Ipamorelin's creation.
Is Ipamorelin still being researched today?
Yes. Ipamorelin continues to be used as a reference compound in preclinical GH axis research, ghrelin receptor pharmacology studies, bone biology research, and metabolic research in animal models.
Peer-Reviewed Citations
- Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
- Ankersen M, Johansen NL, Madsen K, Hansen TK, Raun K, Hansen BS, Andersen PH, Thogersen H, Nielsen KK, Peschke B, Lau J, Lundt BF, Sidelmann UG. "Discovery of a new class of functionally and structurally distinct compounds with growth hormone secretagogue properties." Journal of Medicinal Chemistry. 1998;41(19):3699-3704. doi:10.1021/jm980126l
- Howard AD, Feighner SD, Cully DF, et al. "A receptor in pituitary and hypothalamus that functions in growth hormone release." Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. "Ghrelin is a growth-hormone-releasing acylated peptide from stomach." Nature. 1999;402(6762):656-660. doi:10.1038/45230
- Bowers CY, Sartor AO, Reynolds GA, Badger TM. "On the actions of the growth hormone-releasing hexapeptide, GHRP." Endocrinology. 1991;128(4):2027-2035. doi:10.1210/endo-128-4-2027
- Svensson J, Lall S, Dickson SL, Bengtsson BA, Romer J, Ahnfelt-Ronne I, Ohlsson C, Jansson JO. "The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats." Journal of Endocrinology. 2000;165(3):569-577. doi:10.1677/joe.0.1650569
- Smith RG, Sun Y, Betancourt L, Asnicar M. "Growth hormone secretagogues: prospects and potential pitfalls." Best Practice and Research Clinical Endocrinology and Metabolism. 2004;18(3):333-347. doi:10.1016/j.beem.2004.03.002
Final Disclaimer: Ipamorelin is not approved by the FDA for human or veterinary use. All content is for scientific and educational reference only. Palmetto Peptides sells Ipamorelin exclusively for in vitro and preclinical laboratory research.
Authored by the Palmetto Peptides Research Team | Last Updated: March 27, 2026